Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2008;51:1372-1378
Published online before print March 17, 2008, doi: 10.1161/HYPERTENSIONAHA.107.105718
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
51/5/1372    most recent
HYPERTENSIONAHA.107.105718v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Molnar, G. A.
Right arrow Articles by Fiebeler, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molnar, G. A.
Right arrow Articles by Fiebeler, A.
Related Collections
Right arrow Cell signalling/signal transduction
Right arrow Other Vascular biology

(Hypertension. 2008;51:1372.)
© 2008 American Heart Association, Inc.


Original Articles

Glucocorticoid-Related Signaling Effects in Vascular Smooth Muscle Cells

Gergö A. Molnar; Carsten Lindschau; Galyna Dubrovska; Peter R. Mertens; Torsten Kirsch; Marcus Quinkler; Maik Gollasch; Stefanie Wresche; Friedrich C. Luft; Dominik N. Muller; Anette Fiebeler

From the Medical Faculty of the Charité (G.A.M., G.D., S.W., F.C.L., D.N.M., A.F.), Experimental and Clinical Research Center and Max Delbrück Center, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany; Department of Nephrology and Clinical Immunology (P.R.M.), University Hospital Rheinisch-Westfälische Technische Hochschule-Aachen, Aachen, Germany; Department of Internal Medicine-Nephrology (C.L., T.K.), Hannover University Medical School, Hannover, Germany; 2nd Department of Medicine and Nephrological Center (G.A.M.), University of Pecs, Pecs, Hungary; Section Nephrology/Intensive Care (M.G.), Campus Virchow, Charité, Berlin, Germany; and Section Clinical Endocrinology (M.Q.), Campus Mitte, Charité, Berlin, Germany.

Correspondence to Anette Fiebeler, ECRC and MDC, Robert-Rössle Str 10, 13125 Berlin, Germany. E-mail fiebeler{at}charite.de

Mineralocorticoid receptor blockade protects from angiotensin II–induced target-organ damage. 11β-Hydroxysteroid dehydrogenase type 2 protects the mineralocorticoid receptor from activation by glucocorticoids; however, high glucocorticoid concentrations and absent 11β-hydroxysteroid dehydrogenase type 2 in some tissues make glucocorticoids highly relevant mineralocorticoid receptor ligands. We investigated the effects of corticosterone (10–6 to 10–12 mol/L) on early vascular mineralocorticoid receptor signaling by Western blotting, confocal microscopy, and myography. Corticosterone initiated extracellular signal–regulated kinase 1/2 phosphorylation in rat vascular smooth muscle cells at ≥10–11 mol/L doses. Protein synthesis inhibitors had no effect, indicating a nongenomic action. Corticosterone also stimulated c-Jun N-terminal kinase, p38, Src, and Akt phosphorylation at 15 minutes and enhanced angiotensin II–induced signaling at 5 minutes. A specific epidermal growth factor receptor blocker, AG1478, as well as the Src inhibitor PP2, markedly reduced corticosterone-induced extracellular signal–regulated kinase 1/2 phosphorylation, as did preincubation of cells with the mineralocorticoid receptor antagonist spironolactone. Silencing mineralocorticoid receptor with small interfering RNA abolished corticosterone-induced effects. Corticosterone (10–9 mol/L) enhanced phenylephrine-induced contraction of intact aortic rings. These effects were dependent on the intact endothelium, mineralocorticoid receptor, and mitogen-activated protein kinase kinase 1/extracellular signal-regulated kinase signaling. We conclude that corticosterone induces rapid mineralocorticoid receptor signaling in vascular smooth muscle cells that involves mitogen-activated protein kinase kinase/extracellular signal–regulated kinase–dependent pathways. These new mineralocorticoid receptor–dependent signaling pathways suggest that glucocorticoids may contribute to vascular disease via mineralocorticoid receptor signaling, independent of circulating aldosterone.


Key Words: corticosterone • angiotensin • phenylephrine • mineralocorticoid receptor • epidermal growth factor receptor




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
D. Rizzoni, E. Porteri, C. De Ciuceis, L. F. Rodella, S. Paiardi, N. Rizzardi, C. Platto, G. E. M. Boari, A. Pilu, G. A. M. Tiberio, et al.
Hypertrophic Remodeling of Subcutaneous Small Resistance Arteries in Patients with Cushing's Syndrome
J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 5010 - 5018.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Niizuma, H. Endo, C. Nito, D. J. Myer, G. S. Kim, and P. H. Chan
The PIDDosome mediates delayed death of hippocampal CA1 neurons after transient global cerebral ischemia in rats
PNAS, October 21, 2008; 105(42): 16368 - 16373.
[Abstract] [Full Text] [PDF]